Breaking News, Collaborations & Alliances

Boehringer Partners with Sarah Cannon to Reserach mAbs

Development program will study BI 754091 and BI 754111 mAbs for the combination treatment of multiple cancers

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Boehringer Ingelheim and Sarah Cannon Research Institute have entered a strategic collaboration uniting Boehringer’s cancer drug development experience with Sarah Cannon’s expertise and in designing and optimizing clinical trials. The joint clinical development program will study Boehringer’s BI 754091 (anti- PD-1) and BI 754111 (anti-LAG 3) monoclonal antibodies for the combination treatment of multiple cancers, including non-small cell lung cancer (NSCLC). BI 754091 and BI...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters